The EFEMP2 gene, associated with Cutis Laxa Type 1B, plays a critical role in the development and maintenance of elastic fibers in connective tissue. Mutations in this gene lead to Cutis Laxa Type 1B, an autosomal recessive disorder characterized by loose, sagging skin, and potentially more severe internal complications affecting the lungs, arteries, and gastrointestinal system.
DNA Labs UAE offers a genetic test specifically designed to identify mutations in the EFEMP2 gene, providing crucial information for diagnosing Cutis Laxa Type 1B. This test is particularly valuable for families with a history of the condition or individuals showing symptoms, facilitating early intervention and management strategies.
The cost of the EFEMP2 gene test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the presence of mutations in the EFEMP2 gene, offering peace of mind and the potential for targeted treatments to those affected by Cutis Laxa Type 1B.
The FBLN5 gene is associated with a rare condition known as Cutis Laxa Type 2, which is an autosomal dominant disorder. This condition is characterized by the appearance of loose, sagging skin and can also affect internal organs, leading to a variety of health issues. The FBLN5 gene plays a crucial role in the formation and maintenance of elastic fibers in connective tissue, and mutations in this gene can disrupt these processes, leading to the symptoms observed in Cutis Laxa Type 2.
To diagnose this condition, a genetic test targeting the FBLN5 gene can be conducted. DNA Labs UAE offers this specific genetic test, providing a crucial tool for individuals and families seeking answers about this rare disorder. The test is priced at 4400 AED and involves collecting a DNA sample from the patient, usually through a blood draw or a cheek swab. The sample is then analyzed in the laboratory to identify any mutations in the FBLN5 gene that may be indicative of Cutis Laxa Type 2.
This genetic test is not only important for diagnosing affected individuals but also for understanding the risk of passing the condition on to future generations. With the results, families can make informed decisions regarding health management, potential treatments, and genetic counseling. DNA Labs UAE ensures confidentiality and accuracy in the testing process, providing a crucial service for those impacted by this rare genetic disorder.
The ATP6V0A2 gene cutis laxa type 2A autosomal recessive genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the ATP6V0A2 gene. These mutations are responsible for causing Cutis Laxa type 2A, a rare genetic disorder characterized by loose, sagging skin and, in some cases, additional systemic symptoms affecting various organs. The condition follows an autosomal recessive inheritance pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder.
The test is crucial for early diagnosis, allowing for appropriate management and intervention strategies to be implemented, potentially improving the quality of life for affected individuals. Priced at 4400 AED, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of the specific genetic mutations in the ATP6V0A2 gene.
DNA Labs UAE is equipped with state-of-the-art technology and staffed by genetic experts, ensuring high accuracy and reliability of the test results. This test is not only important for diagnosing affected individuals but also for carrier testing, which can inform family planning decisions for those with a family history of Cutis Laxa type 2A.
The RFXANK Gene Bare Lymphocyte Syndrome Type 2 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the RFXANK gene, which are associated with Bare Lymphocyte Syndrome Type 2 (BLS2). This condition is a rare immunodeficiency disorder that affects the body's ability to effectively respond to infections. The test plays a critical role in the early detection and management of the syndrome, facilitating personalized treatment plans to enhance patient outcomes.
Priced at 4400 AED, the test involves collecting a DNA sample from the patient, usually through a blood draw or a cheek swab, which is then analyzed in the state-of-the-art facilities of DNA Labs UAE. The laboratory utilizes advanced genetic sequencing technologies to accurately identify any mutations in the RFXANK gene, ensuring reliable results for patients and healthcare providers. By opting for this genetic test, individuals suspected of having Bare Lymphocyte Syndrome Type 2 can gain valuable insights into their condition, enabling timely and effective medical interventions.
The CIITA Gene Bare Lymphocyte Syndrome Type 2 Complementation Group A Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE. This test is designed to identify mutations in the CIITA gene, which are associated with Bare Lymphocyte Syndrome Type 2 (BLS2), specifically within complementation group A. BLS2 is a rare immunodeficiency disorder characterized by a reduced expression of major histocompatibility complex (MHC) class II molecules, leading to a severe impairment in the immune system's ability to fight infections.
The CIITA gene plays a crucial role as a master regulator in the expression of MHC class II genes, and mutations in this gene can result in the clinical manifestations of BLS2. Patients with this condition often present with recurrent respiratory and gastrointestinal infections from an early age, underscoring the importance of early diagnosis and intervention.
The test conducted at DNA Labs UAE involves collecting a DNA sample, typically through a blood draw, and analyzing it for specific genetic alterations in the CIITA gene. This genetic testing is essential for confirming the diagnosis of BLS2 in affected individuals, allowing for appropriate management and treatment plans to be put in place.
The cost of the CIITA Gene Bare Lymphocyte Syndrome Type 2 Complementation Group A Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis necessary to provide accurate and reliable results, offering critical insights into the patient's condition and guiding further healthcare decisions.
The FGFR2 Gene Beare-Stevenson Cutis Gyrata Syndrome Genetic Test is a specialized diagnostic assessment conducted to identify mutations in the FGFR2 gene, which are responsible for Beare-Stevenson cutis gyrata syndrome. This rare genetic disorder is characterized by distinctive skin abnormalities, including furrowed and wrinkled skin, craniofacial anomalies, and a variety of other systemic manifestations. The test is crucial for confirming a clinical diagnosis, guiding treatment options, and providing information for family planning.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, this test employs advanced genetic sequencing techniques to analyze the FGFR2 gene for specific mutations. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then meticulously analyzed in the laboratory setting.
The cost of the FGFR2 Gene Beare-Stevenson Cutis Gyrata Syndrome Genetic Test at DNA Labs UAE is set at 4400 AED. This price reflects the comprehensive nature of the test, covering the expenses of the sophisticated genetic analysis and the expertise required to accurately interpret the results. Patients considering this test are advised to consult with a genetic counselor or a healthcare provider specializing in genetics to discuss the potential implications of the test results for themselves and their family members.
The FGFR2 Gene Bent Bone Dysplasia Syndrome Genetic Test is a specialized diagnostic examination offered at DNA Labs UAE, designed to identify mutations in the FGFR2 gene, which are linked to Bent Bone Dysplasia Syndrome. This condition is a rare genetic disorder characterized by skeletal abnormalities, including significantly bent bones, underdeveloped lungs, and other potential complications that can affect a patient's quality of life from a very early age. The test, priced at 4400 AED, involves analyzing the patient's DNA to detect specific genetic alterations in the FGFR2 gene, providing crucial information for accurate diagnosis, management, and genetic counseling for affected families. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test is a vital tool for healthcare providers and families seeking to understand the genetic basis of Bent Bone Dysplasia Syndrome and related skeletal disorders.
The "PLS3 Gene Bone Mineral Density QTL18 Osteoporosis Genetic Test" is a specialized diagnostic tool designed to assess an individual's genetic risk for developing osteoporosis, a condition characterized by weakened bones that are more prone to fracture. This test specifically examines variations in the PLS3 gene, which have been linked to changes in bone mineral density and, consequently, an increased risk of osteoporosis. The QTL18 refers to a specific quantitative trait locus associated with these bone density variations. By analyzing a person's genetic makeup, the test can provide valuable insights into their predisposition to osteoporosis, allowing for early intervention and personalized management strategies to mitigate risk.
The test is available at DNA Labs UAE, a leading facility in genetic testing and analysis. The cost of the test is 4400 AED, reflecting the comprehensive nature of the analysis and the valuable information it provides. Individuals who are concerned about their bone health, have a family history of osteoporosis, or exhibit risk factors for reduced bone density may particularly benefit from this test. The results can guide healthcare professionals in recommending lifestyle changes, dietary adjustments, or treatments to strengthen bone health and prevent osteoporosis.
The LEMD3 Gene Buschke-Ollendorff Syndrome Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the LEMD3 gene, which are linked to the development of Buschke-Ollendorff Syndrome (BOS). BOS is a rare genetic disorder characterized by skin manifestations, such as connective tissue nevi, and osteopoikilosis, a condition where bone density is increased in certain areas, leading to a spotted appearance on X-rays. The test plays a crucial role in confirming the diagnosis of BOS, enabling healthcare providers to offer appropriate management and counseling for affected individuals and their families.
Performed at DNA Labs UAE, a leading facility in genetic testing, the LEMD3 Gene Buschke-Ollendorff Syndrome Genetic Test is conducted through advanced molecular techniques to ensure high accuracy and reliability. The test cost is set at 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results. By opting for this test, patients and their families can gain valuable insights into their genetic health, paving the way for informed medical and personal decisions.
The C1QA gene plays a crucial role in the immune system as part of the C1 complex, which is essential for the activation of the complement system, a part of the immune response that enhances the ability of antibodies and phagocytic cells to clear pathogens from an organism. Mutations in the C1QA gene can lead to C1q deficiency, a rare genetic condition that significantly impairs the immune system, making individuals more susceptible to infections and autoimmune diseases.
To diagnose this condition, the C1QA Gene C1q Deficiency Genetic Test is available at DNA Labs UAE. This specialized genetic test is designed to identify mutations in the C1QA gene, confirming the diagnosis of C1q deficiency. The test is crucial for individuals with a clinical history suggestive of complement system disorders, as it provides a definitive diagnosis, allowing for appropriate management and treatment of the condition.
The cost of the C1QA Gene C1q Deficiency Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, which includes genetic analysis and counseling services to help patients understand their results. The test is performed with a high level of accuracy and precision, providing critical information for the affected individuals and their families regarding the management of the condition and the risk of passing it on to future generations.
